Rezpegaldesleukin showed sustained strong disease control through Week 52 in moderate-to-severe atopic dermatitis (AD) with monthly or quarterly dosing, according to the 36-week blinded maintenance period of the 52-week REZOLVE-AD study.
Nektar’s rezpegaldesleukin is an interleukin ( IL)-2 receptor pathway agonist that selectively expands and enhances the function of regulatory T-cells.
Nektar plans to advance to Phase 3 studies with the goal of submitting a biologics license application (BLA) to the US Food and Drug Administration (FDA) in 2029.
The global REZOLVE-AD Phase 2b study enrolled 393 patients with moderate-to-severe AD. Patients were randomized (3:3:3:2) to receive subcutaneous treatment with three doses of rezpegaldesleukin or placebo for a 16-week induction period.
Following the 16-week induction period, rezpegaldesleukin-treated patients who achieved Eczema Area Severity Index (EASI) percent score reductions of at least 50 were re-randomized (1:1) to continue at the same induction dose given monthly (Q4W) or quarterly (Q12W) through Week 52 in a blinded 36-week maintenance period. Patients that did not achieve an EASI-50 during the 16-week induction period entered into a treatment escape arm for up to 36 weeks.
Monthly or quarterly dosing regimens resulted in sustained disease control for EASI-75, EASI-90, validated Investigator’s Global Assessment of Atopic Dermatitis (vIGA-AD) response, and Itch Numerical Rating Scale (NRS) response, with the 24µg/kg every four-week (Q4W) and 12-week regimens (Q12W) showing the highest maintenance of response at Week 52.
Moreover, a meaningful proportion of patients achieved new EASI-75, EASI-90, Itch NRS, and vIGA-AD 0/1 responses at Week 52, supporting increased disease control with prolonged therapy and less frequent dosing.
In maintenance, a 2- to 5-fold increase in percentage of patients who achieved EASI-100 was observed in the 24 µg/kg Q4W and Q12W dosing regimens. Among all re-randomized patients from Week 16 to Week 52, Q4W maintenance dosing increased EASI-100 response from 4% to 22% and Q12W dosing increased EASI-100 response from 9% to 18%, the study showed. Among re-randomized patients who had an EASI-75 or vIGA-AD response at maintenance baseline, Q4W dosing increased EASI-100 response from 6% to 30% and Q12W dosing increased EASI-100 response from 14% to 27%.
“These data show that rezpegaldesleukin, as a broad-based Treg agonist, is emerging as one of the most important mechanisms in development to treat atopic dermatitis,” says Jonathan Silverberg, MD, PhD, MPH, a Professor of Dermatology at The George Washington University School of Medicine and Health Sciences in Washington, DC, in a news release. “With both monthly and quarterly maintenance dosing, new and sustained responses were observed across the key endpoints of EASI-75, vIGA-0/1, and itch and with a large proportion of patients achieving complete clearance with EASI-100.”
Week 52 Efficacy Measurements in Maintenance
| Maintenance of Response Among Re-Randomized Patients Achieving EASI-50 in 16-Week Induction | ||||
| 24 µg/kg Q4W (pooled) | 24 µg/kg Q12W (pooled) | 18 µg/kg Q4W | 18 µg/kg Q12W | |
| Number of Patients | N=55 | N=56 | N=28 | N=28 |
| EASI-75 | 71%
(n=36) |
83%
(n=35) |
81%
(n=20) |
76%
(n=19) |
| EASI-90 | 80%
(n=18) |
78%
(n=20) |
57%
(n=8) |
57%
(n=7) |
| vIGA-AD 0/1 | 85%
(n=14) |
63%
(n=21) |
81%
(n=12) |
62%
(n=9) |
| Itch NRS* | 75%
(n=25) |
77%
(n=17) |
56%
(n=14) |
61%
(n=6) |
| N=xx is the entire maintenance population; (n=xx) is the denominator which equals the number of responders at Week 16; % represents proportion of patients who maintained that response at Week 52
|
||||
| *Only patients with baseline Itch NRS ≥ 4 were used as denominators for assessing Itch NRS response | ||||
|
New Responses Among Re-Randomized Patients Achieving EASI-50 in 16-Week Induction |
||||
| 24 µg/kg Q4W (pooled) | 24 µg/kg Q12W (pooled) | 18 µg/kg Q4W | 18 µg/kg Q12W | |
| Number of Patients | N=55 | N=56 | N=28 | N=28 |
| EASI-75 | 51%
(n=19) |
39%
(n=21) |
17%
(n=8) |
62%
(n=9) |
| EASI-90 | 33%
(n=37) |
26%
(n=36) |
37%
(n=20) |
33%
(n=21) |
| vIGA-AD 0/1 | 41%
(n=41) |
40%
(n=35) |
23%
(n=16) |
36%
(n=19) |
| Itch NRS* | 33%
(n=26) |
18%
(n=32) |
31%
(n=13) |
18%
(n=17) |
| N=xx is the entire maintenance population; (n=xx) is the denominator which equals the number of responders at Week 16; % represents proportion of patients who maintained that response at Week 52
|
||||
| *Only patients with baseline Itch NRS ≥ 4 were used as denominators for assessing Itch NRS response | ||||
“These data highlight that rezpegaldesleukin offers a completely novel therapeutic modality for the potential treatment of atopic dermatitis with numerous advantages to existing classes,” adds David Rosmarin, MD, the Chair of the Department of Dermatology and Associate Professor of Dermatology at Indiana University School of Medicine in Indianapolis, Indiana. “Importantly, we don’t see any increased risk of incidence of conjunctivitis, oral herpes, oral ulcers, or malignancies with this MOA, as has been observed with other mechanisms. The investigators are looking forward to initiating Phase 3 studies as quickly as possible.”
“These new REZOLVE-AD study results reinforce the promise of the Treg mechanism to treat atopic dermatitis,” says Howard W. Robin, President and CEO of Nektar Therapeutics. “In the induction part of REZOLVE-AD, we saw a rapid onset of EASI-75 response and itch relief early in treatment, and, for the first time with Tregs, we observed meaningful improvement in self-reported asthma control in patients with co-morbid asthma. The combined data from induction and maintenance now showcase the potential of a Treg biologic to offer compelling efficacy and safety advantages and less frequent maintenance dosing as compared to current mechanisms. We look forward to advancing to Phase 3 studies quickly with the goal of submitting a BLA in 2029.”
The safety profile of rezpegaldesleukin in maintenance was consistent with observations from the induction part of the study.
Rezpegaldesleukin was well-tolerated with no new safety concerns identified during the 36-week maintenance and escape periods. The discontinuation rate due to adverse events was 3.5% for all aggregated patients. Overall rates of treatment-emergent adverse events (TEAEs) were 72% for re-randomized rezpegaldesleukin-treated patients, 65% for placebo patients in maintenance, and 83% for all escape patients. The most frequent TEAE was injection-site reactions, nearly all of which were mild (77%), and which occurred at a lower rate and frequency than observed in the initial induction part of the study (discontinuation rate due to injection-site reactions was 0.7%).
In February 2025, the FDA granted Fast Track designation for rezpegaldesleukin for the treatment of adult and pediatric patients 12 years of age and older with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. In July 2025, the FDA granted Fast Track designation for rezpegaldesleukin for the treatment of severe alopecia areata (AA) in adults and pediatric patients 12 years of age and older who weigh at least 40kg.
Rezpegaldesleukin is being developed as a self-administered injection for a number of autoimmune and inflammatory diseases. It is wholly owned by Nektar Therapeutics.
The Dermatology Digest recently reported on the induction part of REZOLVE-AD.